Bifunctional Cereblon Compounds Bridging E3 Ligase and Target Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as multiple myeloma and cancers are limited by the inability to effectively target and modulate certain classes of proteins, particularly transcription factors, due to the challenges in disrupting protein-protein interactions and the specificity required for therapeutic efficacy.
Innovation Solution
Development of bifunctional compounds, known as PROTACs, that recruit endogenous proteins to E3 Ubiquitin Ligases for degradation, utilizing a cereblon E3 Ubiquitin Ligase binding moiety (CLM) and a protein targeting moiety (PTM) to place target proteins in proximity for ubiquitination and degradation by the proteasome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If small molecules are used to target E3 ligases, then substrate specificity for ubiquitination is improved, but the ability to disrupt protein-protein interactions is worsened due to large contact surfaces and shallow grooves
Solution Approach 1:
The invention divides the problem of targeting E3 ligases into two separate functional moieties: a cereblon-binding moiety (CBM) that specifically binds to the E3 ligase cereblon, and a protein-targeting moiety (PTM) that binds to the desired protein substrate. This segmentation allows each moiety to independently optimize its binding function, overcoming the challenge of disrupting large protein-protein interaction surfaces with small molecules.
Solution Approach 2:
The bifunctional compound acts as an intermediary that bridges the E3 ligase cereblon and the target protein through covalent linkage. This intermediary structure brings the target protein into proximity with the E3 ligase active site, enabling ubiquitination without requiring the small molecule to directly disrupt the entire protein-protein interaction interface.
2Reliability
If bifunctional compounds are developed to target specific proteins, then therapeutic efficacy is improved, but device complexity increases due to the need for both E3 ligase binding and protein targeting moieties
Solution Approach 1:
The cereblon-binding moiety (CBM) serves as a universal anchor that binds to the E3 ligase cereblon, which is constitutively present in cells. This universal binding element can be combined with different protein-targeting moieties (PTMs) to create bifunctional compounds against various disease targets, reducing overall development complexity through platform technology.
Solution Approach 2:
The bifunctional compound is constructed as a composite structure combining two distinct functional elements: the CBM (based on thalidomide or lenalidomide derivatives) and the PTM (specific ligand for the target protein). This composite design allows each component to contribute its specialized binding function while being linked through a suitable connector group.
Data Source
AI summary
The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.